<p>GeneDx Holdings Corp.（纳斯达克代码：WGS - 获取免费报告）在周四的交易中股价上涨了 10.7%。该公司股价最高达到 40.10 美元，最后交易价格为 38.4350 美元。在午盘交易中，约有 2,643,775 股成交，较平均每日成交量 936,591 股增加了 182%。该股票之前的收盘价为 34.71 美元。</p>
<h2>分析师评级变动</h2>
<ul>
<li>生物科技催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
<p>多位研究分析师最近对 WGS 股票发表了评论。BTIG Research 将 GeneDx 的目标股价从 170.00 美元下调至 90.00 美元，并在周二的研究报告中给予该公司 “买入” 评级。Craig Hallum 在周二的研究报告中重申了 “买入” 评级，并对 GeneDx 的目标股价设定为 85.00 美元。华尔街 Zen 在 2 月 8 日的研究报告中将 GeneDx 的评级从 “买入” 下调至 “持有”。Guggenheim 在周二的研究报告中将 GeneDx 的目标股价从 100.00 美元下调至 70.00 美元，并给予该公司 “买入” 评级。最后，Jefferies Financial Group 在 2 月 23 日的研究报告中对 GeneDx 设定了 150.00 美元的目标股价。七位研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 96.43 美元。</p>
<p><strong>阅读我们关于 WGS 的最新研究报告</strong></p>
<h2>GeneDx 股价上涨 16.7%</h2>
<ul>
<li>GeneDx：即使在 2024 年上涨了 2700% 之后，仍有上涨空间</li>
</ul>
<p>该公司的市值为 11.9 亿美元，市盈率为-15.11，贝塔值为 2.06。公司的债务与股本比率为 0.38，速动比率为 2.34，流动比率为 3.09。该公司的 50 日移动平均线为 69.45 美元，200 日移动平均线为 106.00 美元。</p>
<p>GeneDx（纳斯达克代码：WGS - 获取免费报告）最近在 5 月 4 日公布了其财报。该公司报告季度每股收益为（0.28 美元），低于市场共识预期的（0.06 美元）22 美分。该公司季度收入为 1.0225 亿美元，而市场共识预期为 1.1246 亿美元。GeneDx 的股本回报率为 9.15%，净利润率为-17.58%。在去年同期，该公司每股收益为（0.23 美元）。作为一个整体，股票研究分析师预计 GeneDx Holdings Corp.在当前财年将发布 0.75 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他 GeneDx 新闻中，首席财务官 Kevin Feeley 在 4 月 29 日的交易中出售了 392 股 GeneDx 股票。这些股票以平均 65.19 美元的价格出售，总价值为 25,554.48 美元。出售完成后，首席财务官持有 34,942 股公司股票，价值为 2,277,868.98 美元。此次交易使其持股减少了 1.11%。该出售在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站获取。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。此外，首席执行官 Katherine Stueland 在 4 月 29 日的交易中出售了 2,172 股 GeneDx 股票。该股票以平均 65.19 美元的价格出售，总交易额为 141,592.68 美元。出售完成后，首席执行官持有 93,216 股公司股票，价值为 6,076,751.04 美元。此次交易使其持股减少了 2.28%。该出售的 SEC 文件提供了更多信息。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。内部人士在上个季度出售了 104,028 股公司股票，价值为 7,377,165 美元。目前 29.60% 的股票由公司内部人士持有。</p>
<h2>GeneDx 的机构交易</h2>
<p>对冲基金和其他机构投资者最近买卖了该公司的股票。Jones Financial Companies Lllp 在第三季度将其在 GeneDx 的持股增加了 664.3%。Jones Financial Companies Lllp 现在拥有 214 股公司股票，价值 25,000 美元，此前在上个季度又购买了 186 股。Kestra Advisory Services LLC 在第四季度获得了 GeneDx 的新股份，价值约 27,000 美元。Fifth Third Bancorp 在第一季度获得了 GeneDx 的新股份，价值约 31,000 美元。Quarry LP 在第三季度将其在 GeneDx 的持股增加了 248.8%。Quarry LP 现在拥有 293 股公司股票，价值 32,000 美元，此前在上个季度又购买了 209 股。最后，Ramirez Asset Management Inc.在第四季度获得了 GeneDx 的新股份，价值约 33,000 美元。机构投资者和对冲基金持有该公司 61.72% 的股票。</p>
<h2>关于 GeneDx</h2>
<p>（获取免费报告）</p>
<p>GeneDx 是一家临床诊断公司，专注于罕见和遗传疾病的全面基因和基因组检测。该公司提供广泛的检测组合，包括靶向基因面板、全外显子组测序、全基因组测序和染色体微阵列分析。GeneDx 的实验室服务通过提供详细的变异解释和报告，支持对从罕见儿童疾病和遗传性癌症综合症到神经肌肉和代谢疾病等广泛病症的诊断。</p>
<p>GeneDx 成立于 2000 年，总部位于马里兰州盖瑟斯堡，旨在加速基因组发现向临床护理的转化。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 GeneDx 更具投资价值</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GeneDx 吗？</h2>
<p>在考虑 GeneDx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 GeneDx 并不在名单上。</p>
<p>虽然 GeneDx 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

<p>GeneDx Holdings Corp.（纳斯达克代码：WGS）股价上涨 10.7%，至 38.43 美元，交易量增加了 182%。分析师的评级不一，目标价范围从 70 美元到 170 美元不等。公司报告每股亏损 0.28 美元，未达到预期，收入为 1.0225 亿美元。内部人士出售股票以支付税务义务，机构投资者显著增加了持股。GeneDx 的市值为 11.9 亿美元，分析师的平均评级为 “适度买入”</p>

<p>GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) shares were up 10.7% during trading on Thursday . The company traded as high as $40.10 and last traded at $38.4350. Approximately 2,643,775 shares changed hands during mid-day trading, an increase of 182% from the average daily volume of 936,591 shares. The stock had previously closed at $34.71.</p>
<div class="lb-trans"><p>GeneDx Holdings Corp.（纳斯达克代码：WGS - 获取免费报告）在周四的交易中股价上涨了 10.7%。该公司股价最高达到 40.10 美元，最后交易价格为 38.4350 美元。在午盘交易中，约有 2,643,775 股成交，较平均每日成交量 936,591 股增加了 182%。该股票之前的收盘价为 34.71 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
</div><p>A number of research analysts have recently commented on WGS shares. BTIG Research decreased their price objective on shares of GeneDx from $170.00 to $90.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. Craig Hallum reissued a &#34;buy&#34; rating and issued a $85.00 price objective on shares of GeneDx in a research report on Tuesday. Wall Street Zen downgraded shares of GeneDx from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, February 8th. Guggenheim decreased their price objective on shares of GeneDx from $100.00 to $70.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. Finally, Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research report on Monday, February 23rd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $96.43.</p>
<div class="lb-trans"><p>多位研究分析师最近对 WGS 股票发表了评论。BTIG Research 将 GeneDx 的目标股价从 170.00 美元下调至 90.00 美元，并在周二的研究报告中给予该公司 “买入” 评级。Craig Hallum 在周二的研究报告中重申了 “买入” 评级，并对 GeneDx 的目标股价设定为 85.00 美元。华尔街 Zen 在 2 月 8 日的研究报告中将 GeneDx 的评级从 “买入” 下调至 “持有”。Guggenheim 在周二的研究报告中将 GeneDx 的目标股价从 100.00 美元下调至 70.00 美元，并给予该公司 “买入” 评级。最后，Jefferies Financial Group 在 2 月 23 日的研究报告中对 GeneDx 设定了 150.00 美元的目标股价。七位研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 96.43 美元。</p>
</div><p><strong>Read Our Latest Research Report on WGS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 WGS 的最新研究报告</strong></p>
</div><h2>GeneDx Stock Up 16.7%</h2>
<div class="lb-trans"><h2>GeneDx 股价上涨 16.7%</h2>
</div><ul>
<li>GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play</li>
</ul>
<div class="lb-trans"><ul>
<li>GeneDx：即使在 2024 年上涨了 2700% 之后，仍有上涨空间</li>
</ul>
</div><p>The firm has a market cap of $1.19 billion, a P/E ratio of -15.11 and a beta of 2.06. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.34 and a current ratio of 3.09. The firm's fifty day moving average is $69.45 and its 200 day moving average is $106.00.</p>
<div class="lb-trans"><p>该公司的市值为 11.9 亿美元，市盈率为-15.11，贝塔值为 2.06。公司的债务与股本比率为 0.38，速动比率为 2.34，流动比率为 3.09。该公司的 50 日移动平均线为 69.45 美元，200 日移动平均线为 106.00 美元。</p>
</div><p>GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the previous year, the firm posted ($0.23) EPS. As a group, equities research analysts anticipate that GeneDx Holdings Corp. will post 0.75 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>GeneDx（纳斯达克代码：WGS - 获取免费报告）最近在 5 月 4 日公布了其财报。该公司报告季度每股收益为（0.28 美元），低于市场共识预期的（0.06 美元）22 美分。该公司季度收入为 1.0225 亿美元，而市场共识预期为 1.1246 亿美元。GeneDx 的股本回报率为 9.15%，净利润率为-17.58%。在去年同期，该公司每股收益为（0.23 美元）。作为一个整体，股票研究分析师预计 GeneDx Holdings Corp.在当前财年将发布 0.75 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other GeneDx news, CFO Kevin Feeley sold 392 shares of GeneDx stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $65.19, for a total value of $25,554.48. Following the completion of the sale, the chief financial officer owned 34,942 shares in the company, valued at $2,277,868.98. The trade was a 1.11% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 2,172 shares of GeneDx stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total transaction of $141,592.68. Following the completion of the sale, the chief executive officer owned 93,216 shares of the company's stock, valued at $6,076,751.04. This trade represents a 2.28% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 104,028 shares of company stock worth $7,377,165 in the last quarter. 29.60% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 GeneDx 新闻中，首席财务官 Kevin Feeley 在 4 月 29 日的交易中出售了 392 股 GeneDx 股票。这些股票以平均 65.19 美元的价格出售，总价值为 25,554.48 美元。出售完成后，首席财务官持有 34,942 股公司股票，价值为 2,277,868.98 美元。此次交易使其持股减少了 1.11%。该出售在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站获取。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。此外，首席执行官 Katherine Stueland 在 4 月 29 日的交易中出售了 2,172 股 GeneDx 股票。该股票以平均 65.19 美元的价格出售，总交易额为 141,592.68 美元。出售完成后，首席执行官持有 93,216 股公司股票，价值为 6,076,751.04 美元。此次交易使其持股减少了 2.28%。该出售的 SEC 文件提供了更多信息。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。内部人士在上个季度出售了 104,028 股公司股票，价值为 7,377,165 美元。目前 29.60% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of GeneDx</h2>
<div class="lb-trans"><h2>GeneDx 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp raised its stake in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after purchasing an additional 186 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in GeneDx in the 4th quarter worth about $27,000. Fifth Third Bancorp acquired a new stake in GeneDx in the 1st quarter worth about $31,000. Quarry LP raised its stake in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company's stock worth $32,000 after purchasing an additional 209 shares in the last quarter. Finally, Ramirez Asset Management Inc. acquired a new stake in GeneDx in the 4th quarter worth about $33,000. Institutional investors and hedge funds own 61.72% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买卖了该公司的股票。Jones Financial Companies Lllp 在第三季度将其在 GeneDx 的持股增加了 664.3%。Jones Financial Companies Lllp 现在拥有 214 股公司股票，价值 25,000 美元，此前在上个季度又购买了 186 股。Kestra Advisory Services LLC 在第四季度获得了 GeneDx 的新股份，价值约 27,000 美元。Fifth Third Bancorp 在第一季度获得了 GeneDx 的新股份，价值约 31,000 美元。Quarry LP 在第三季度将其在 GeneDx 的持股增加了 248.8%。Quarry LP 现在拥有 293 股公司股票，价值 32,000 美元，此前在上个季度又购买了 209 股。最后，Ramirez Asset Management Inc.在第四季度获得了 GeneDx 的新股份，价值约 33,000 美元。机构投资者和对冲基金持有该公司 61.72% 的股票。</p>
</div><h2>About GeneDx</h2>
<div class="lb-trans"><h2>关于 GeneDx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.</p>
<div class="lb-trans"><p>GeneDx 是一家临床诊断公司，专注于罕见和遗传疾病的全面基因和基因组检测。该公司提供广泛的检测组合，包括靶向基因面板、全外显子组测序、全基因组测序和染色体微阵列分析。GeneDx 的实验室服务通过提供详细的变异解释和报告，支持对从罕见儿童疾病和遗传性癌症综合症到神经肌肉和代谢疾病等广泛病症的诊断。</p>
</div><p>Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.</p>
<div class="lb-trans"><p>GeneDx 成立于 2000 年，总部位于马里兰州盖瑟斯堡，旨在加速基因组发现向临床护理的转化。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than GeneDx</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 GeneDx 更具投资价值</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GeneDx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GeneDx 吗？</h2>
</div><p>Before you consider GeneDx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GeneDx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 GeneDx 并不在名单上。</p>
</div><p>While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GeneDx 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GeneDx（NASDAQ 代码：WGS）股价上涨 10.7% - 以下是发生的事情